Molecular diagnostics-An emerging frontier in dermatopathology

American Journal of Dermatopathology

Volumn 33, Issue 1, 2011, Pages 1-16

  Dadzie, Ophelia E ^a   Neat, Michael ^b   Emley, Andrew ^c   Bhawan, Jag ^c   Mahalingam, Meera ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytogenetics; Dermatopathology; genomics; molecular diagnostics; proteomics

Indexed keywords

IMATINIB; MICROSATELLITE DNA;

ALOPECIA; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME BAND; COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL DIAGNOSIS; EPIDERMOLYSIS BULLOSA; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY LOSS; HUMAN; ICHTHYOSIS; LASER MICRODISSECTION; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MERKEL CELL TUMOR; MOLECULAR DIAGNOSIS; MUIR TORRE SYNDROME; MUTATIONAL ANALYSIS; MYCOSIS FUNGOIDES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOMICS; SEZARY SYNDROME; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN LYMPHOMA; SOFT TISSUE TUMOR; SYSTEMIC SCLEROSIS; TISSUE MICROARRAY;

DERMATOLOGY; GENOMICS; HUMANS; PATHOLOGY; PATHOLOGY, MOLECULAR; PROTEOMICS; SKIN DISEASES;

EID: 78951478949     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181d7a2c0     Document Type: Article

References (127)

1. Hillan KJ, Quirke P. Preface to genomic pathology - a new frontier. J Pathol. 2001;195:1-2.
2. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52:743-775.
3. Carlson JA, Ross JS, Slominski A. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol. 2009; 27:75-102.
4. Dietel M, Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular biology. A review. Virchows Arch. 2006;448:744-755.
5. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131:852-863.
6. Ushiki T, Hoshi O, Iwai K, et al. The structure of human metaphase chromosomes: its histological perspective and new horizons by atomic force microscopy. Arch Histol Cytol. 2002;65:377-390.
7. Wang N. Methodologies in cancer cytogenetics and molecular cytogenetics. Am J Med Genet. 2002;115:118-124.
8. Smeets DF. Historical prospective of human cytogenetics: from microscope to microarray. Clin Biochem. 2004;37:439-446.
9. Sra KK, Babb-Tarbix M, Aboutalebi S, et al. Molecular diagnosis of cutaneous diseases. Arch Dermatol. 2005;141:225-241.
10. Carless MA, Griffiths LR. Cytogenetics of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:227-240.
11. Karenko L, Hyytinen E, Sarna S, et al. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol. 1997;108:22-29.
12. Mao X, Lillington DM, Czepulkowski B, et al. Molecular cytogenetic characterization of Sézary syndrome. Genes Chromosomes Cancer. 2003;36:250-260.
13. Hameed M. Pathology and genetics of adipocytic tumors. Cytogenet Genome Res. 2007;118:138-147.
14. Liehr T, Claussen U. Current developments in human molecular cytogenetic techniques. Curr Mol Med. 2002;2:283-297.
15. Teixeira MR. Combined classical and molecular cytogenetic analysis of cancer. Eur J Cancer. 2002;38:1580-1584.
16. Jain KK. Current status of fluorescent in-situ hybridisation. Med Device Technol. 2004;15:14-17.
17. Halling KC, Kipp BR. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol. 2007;38:1137-1144.
18. Braun-Falco M, Schempp W, Weyers W. Molecular diagnosis in dermatopathology: what makes sense, and what doesnt? Exp Dermatol. 2009;18:12-23.
19. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005;6:782-792.
20. Gellrich S, Ventura R, Jones M, et al. Immunofluorescent and FISH analysis of skin biopsies. Am J Dermatopathol. 2004;26:242-247.
21. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48:13-21.
22. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146-1156.
23. Newman MD, Lertsburapa T, Mirzabeigi M, et al. Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod Pathol. 2009;22:989-995.
24. Newman MD, Mirzabeigi M, Gerami P. Chromosomal copy number changes supporting the classification of lentiginous junctional melanoma of the elderly as a subtype of melanoma.Mod Pathol. 2009;22:1258-1262.
25. Morey AL, Murali R, McCarthy SW, et al. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridization. Pathology. 2009;41:383-387.
26. Sra KK, Torres G, Rady P, et al. Molecular diagnosis of infectious diseases in dermatology. J Am Acad Dermatol. 2005;53:749-765.
27. Oostlander AE, Meijer GA, Yistra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin Genet. 2004;66:488-495.
28. Bejjani BA, Shaffer LG. Application of array-based comparative genomic hybridization to clinical diagnostics. J Mol Diagn. 2006;8:528-533.
29. Beaudet AL, Belmont JW. Array-based DNA diagnostics: let the revolution begin. Annu Rev Med. 2008;59:113-129.
30. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170-2175.
31. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumours based on DNA copy number changes. Am J Pathol. 2003;163: 1765-1770.
32. Bauer J, Bastian BC. Distinguishing melanocytic naevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19:40-49.
33. Murphy MJ, Jen M, Chang MW, et al. Molecular diagnosis of a benign proliferative nodule developing in a congenital melanocytic nevus in a 3-month-old infant. J Am Acad Dermatol. 2008;59:518-523.
34. Emmert-buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996;274:998-1001.
35. Fend F, Raffeld M. Laser capture microdissection in pathology. J Clin Pathol. 2000;53:666-672.
36. Eltoum IA, Siegal GP, Frost AR. Microdissection of histologic sections: past, present and future. Adv Anat Pathol. 2002;9:316-322.
37. Yazdi AS, Puchta U, Flaig M, et al. Laser-capture microdissection: applications in routine molecular dermatopathology. J Cutan Pathol. 2004;31:465-470.
38. Esposito G. Complementary techniques: laser capture microdissection- increasing specificity of gene expression profiling of cancer specimens. Adv Exp Med Biol. 2007;593:54-65.
39. Espina V, Wulfkuhle JD, Calvert VS, et al. Laser-capture microdissection. Nat Protoc. 2006;1:586-603.
40. Espina V, Heiby M, Pierobon M, et al. Laser capture microdissection technique. Expert Rev Mol Diagn. 2007;7:647-657.
41. Murray GI. An overview of laser microdissection technologies. Acta Histochem. 2007;109:171-176.
42. Burgemeister R. New aspects of laser microdissection in research and routine. J Histochem Cytochem. 2005;53:409-412.
43. Dadzie OE, Yang S, Emley A, et al. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanomaclues to melanomagenesis. Br J Dermatol. 2009;160:368-375.
44. Lander ES. Array of hope. Nat Genet. 1999;21:3-4.
45. Choudhuri S. Microarrays in biology and medicine. J Biochem Mol Toxicol. 2004;18:171-179.
46. Koh SS, Opel ML,Wei J-PJ, et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. Mod Pathol. 2009;22:538-546.
47. Sellheyer K, Belbin TJ. DNA microarrays: from structural genomics to functional genomics. The application of gene chips in dermatology and dermatopathology. J Am Acad Dermatol. 2004;51:681-692.
48. Kunz M, Ibrahim SM, Koczan D, et al. DNA microarray technology and its applications in dermatology. Exp Dermatol. 2004;13:593-606.
49. Cheung VG, Morley M, Aguilar F, et al. Making and reading microarrays. Nat Genet. 1999;21:S15-S19.
50. Wessagowit V, South AP. Dermatological applications of DNA array technology. Clin Exp Dermatol. 2002;27:485-492.
51. Trevino V, Falciani F, Barrera-Saldaña HA. DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol Med. 2007;13: 527-541.
52. Dooley TP, Reddy SP, Wilborn TW, et al. Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR. Biochem Biophys Res Commun. 2003;306:1026-1036.
53. Li X, Quigg RJ, Zhou J, et al. Clinical utility of microarrays: current status, existing challenges and future outlook. Curr Genomics. 2008;9: 466-474.
54. Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13: 477-493.
55. Van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology. 2004;44:97-108.
56. Fernández PL, Nayach I, Fernández E, et al. Tissue macroarrays (microchops) for gene expression analysis. Virchows Arch. 2001;438: 591-594.
57. Waterworth A, Horgan K, Speirs V, et al. Tissue microarrays-big potential from small samples (review). Int J Oncol. 2004;25:167-171.
58. Braunschweig T, Chung JY, Hewitt SM. Perspectives in tissue microarrays. Comb Chem High Throughput Screen. 2004;7:575-585.
59. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med. 2005;144:257-268.
60. Kumar B, De Silva M, Venter DJ, et al. Tissue microarrays: a practical guide. Pathology. 2004;36:295-300.
61. Kajdacsy-Balla A, Geynisman JM, Macias V, et al. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol. 2007;38: 113-121.
62. Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001:195:72-79.
63. Rimm DL, Camp RL, Charette LA, et al. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol. 2001;70:255-264.
64. Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002;30:1365-1372.
65. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:1044-1052.
66. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of b-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350-1354.
67. Powledge TM. The polymerase chain reaction. Adv Physiol Educ. 2004; 28:44-50.
68. Hunt JL. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch Pathol Lab Med. 2008;132:248-260.
69. Jin L, Lloyd RV. In situ hybridization: methods and applications. J Clin Lab Anal. 1997;11:2-9.
70. Milbury CA, Li J, Makrigiorgos GM. PCR-basedmethodsfor the enrichment of minority alleles and mutations. Clin Chem. 2009;55:632-640.
71. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22:2671-2680.
72. Sra KK, Torres G, Rady P, et al. Molecular diagnosis of infectious diseases in dermatology. J Am Acad Dermatol. 2005;53:749-765.
73. Tomlison IPM, Lambros MBK, Roylance RR. Loss of heterozygosity analysis: practically and conceptually flawed. Genes Chromosomes Cancer. 2002;34:349-353.
74. Wain EM, Mitchell TJ, Russell-Jones R, et al. Fine mapping of chromosome 10q deletions in mycosis fungoides and Sezary syndrome: identification of two discrete regions of deletion at 10q23.33-24.1 and 10q24.33-25.1. Genes Chromosomes Cancer. 2005;42:184-192.
75. Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nat Genet. 2003;S33:311-323.
76. Chatterjee DK, LaBaer J. Protein technologies. Curr Opin Biotechnol. 2006;17:334-336.
77. Campbell CJ, Wittrup KD. Protein technologies. Curr Opin Biotechnol. 2007;18:293-294.
78. Maercker C. Protein arrays in functional genome research. Biosci Rep. 2005;25:57-70.
79. Somani AK, Somani N. Toponomics: visualizing cellular protein networks in health and disease - a single picture is worth more than a thousand words!. J Cutan Pathol. 2008;35:791-793.
80. Berghoff A, Conrads T, Radfar A, et al. Proteomic characterization of fibrohistiocytic tumours. Abstracts presented at the 45th Annual Meeting of the American Society of Dermatopathology. J cutan Pathol. 2009;36: 104-181.
81. Clausen OP, Aass HCD, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2008;126: 2308-2315.
82. Karenko L, Hahtola S, Ranki A. Molecular cytogenetics in the study of cutaneous T-cell lymphoma. Cytogenet Genome Res. 2007;118:353-361
83. Plaza JA, Morrison C, Magro C. Assessment of TCR-beta clonality in a diverse group of cutaneous T-cell infiltrates. J Cutan Pathol. 2008;35: 358-365.
84. Thurber SE, Zhang B, Kim YH. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57:782-790.
85. Ponti R, Fierro MT, Quaglino P, et al. TCR-chain gene rearrangement by PCR-based Genescan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples. J Invest Dermatol. 2008;128:1030-1038.
86. Cozzio A, French LE. T-cell clonality assays: how do they compare? J Invest Dermatol. 2008;128:771-773.
87. Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002;100:3369-3373.
88. Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol. 2008;35:349-352.
89. Dadzie O, Goerig J, Bhawan J. Incidental microscopic foci of nevic aggregates in skin. Am J Dermatopathol. 2008;30:45-50.
90. Da Forno PD, Fletcher A, Pringle JH, et al. Understanding spitzoid tumours: new insights from molecular pathology. Br J Dermatol. 2008;158:4-14.
91. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
92. Tatlidil C, Parkhill WS, Giacomantonio CA, et al. Detection of tyrosinase mRNA in the sentinel lymph nodes of melanoma patients is not a predictor of short-term disease recurrence. Mod Pathol. 2007;20:427-434.
93. Rangel J, Nosrati M, Leong SP, et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol. 2008;32:1207-1212.
94. Singh M, Lin J, Hocker TL, et al. Genetics of melanoma tumorigenesis. Br J Dermatol. 2008;158:15-21.
95. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21:492-493.
96. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5: e120.
97. Dadzie O, Teixeira F. What can primary cutaneous neuroendocrine carcinoma with squamoid and neuroendocrine differentiation teach us about the origin of Merkel cells? Int J Dermatol. 2009;48:91-93.
98. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096-1100.
99. Garneski KM, Warcola AH, Feng Q, et al. Merkel cell polyomavirus is more frequently present in North America than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129:246-248.
100. Becker JC, Houben R, Ugurel S, et al. MC Polyomavirus is frequently present in Merkel cell carcinoma in European patients. J Invest Dermatol. 2009;129:248-250.
101. Kassem A, Schöpflin A, Diaz C, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008;68:5009-5013.
102. Foulonge V, Dereuvre O, Kluger N, et al. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol. 2009. [epub ahead of print].
103. Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:938-945.
104. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164.
105. Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol. 2007;13:301-319.
106. Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene. 2008;27: 6313-6321.
107. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009; 36:613-619.
108. Lisovsky M, Hoang MP, Dresser KA, et al. Apolipoprotein D in CD34- positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod Pathol. 2008;21:31-38.
109. Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008;21:943-949.
110. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol. 2008; 26:1757-1759.
111. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008;21(S2):S31-S36.
112. Lozano E, Segarra M, Cid MC. Stimulatory autoantibodies to the PDGF receptor in scleroderma. N Engl J Med. 2006;355:278-279.
113. Bibi Y, Gottlieb AB. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J Am Acad Dermatol. 2008;59:654-658.
114. US National Institutes of Health. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed February 28, 2009.
115. Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655-1657.
116. Mirmirani P,Willey A, Headington JT, et al. Primary cicatricial alopecia: histopathologic findings do not distinguish clinical variants. J Am Acad Dermatol. 2005;52:637-643.
117. Van Steensel MA, Happle R, Steijlen PM. Molecular genetics of the hair follicle: the state of the art. Proc Soc Exp Biol Med. 2000;223:1-7.
118. Pozdnyakova O, Mahalingam M. Involvement of the bulge region in primary scarring alopecia. J Cutan Pathol. 2008;35:922-925.
119. Rushan X, Fei H, Zhirung M, et al. Identification of proteins involved in aggregation of human dermal papilla cells by proteomics. J Dermatol Sci. 2007;48:189-197.
120. Poljak M, Seme K, Gale N. Detection of human papilloma viruses in tissue specimens. Adv Anat Pathol. 1998;5:216-234.
121. Arora SK, Kumar B, Sehgal S. Development of a polymerase chain reaction dot-blotting system for detecting cutaneous tuberculosis. Br J Dermatol. 2000;142:72-76.
122. Behrhof W, Springer E, Bräuninger W, et al. PCR testing for treponema pallidum in paraffin-embedded skin biopsy specimens: test design and impact on the diagnosis of syphilis. J Clin Pathol. 2008;61:390-395.
123. Tan SH, Tan HH, Sun YJ, et al. Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids. Ann Acad Med Singapore. 2003;30:3-10.
124. Richard G. Molecular genetics of the ichthyoses. Am J Med Genet C Semin Med Genet. 2004;131C:32-44.
125. Leclerc-Mercier S, Bodemer C, Bourdon-Lanoy E, et al. Early skin biopsy is helpful for the diagnosis and management of neonatal and infantile erythroderma. J Cutan Pathol. 2009. [Epub ahead of print].
126. Featherstone C. Epidermolysis bullosa from fundamental molecular biology to clinical therapies. J Invest Dermatol. 2007;127:256-259.
127. Uitto J. Progress in heritable skin diseases: transational implications of mutational analysis and prospects of molecular therapies. Acta Derm Venereol. 2009;89:228-235.